Joshua D. Palmer: TURBO-NSCLC study looking at TKI alone or combination with SRS for brain metastasis

Joshua D. Palmer, Radiation Oncologist and Associate Professor at The Ohio State University Wexner Medical Center, shared a post on X about a recent paper by Luke R.G. Pike et al., commenting:

“Check out the TURBO-NSCLC study looking at Up-Front next generation Tyrosine kinase inhibitors (TKI) alone or combination with Stereotactic radiosurgery (SRS) for brain metastasis. We found that combination with SRS had better local control and time to progression especially for lesions >1cm.”

Tyrosine Kinase Inhibitors with and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC) published in ASCO Publications.

Authors: Luke R.G. Pike, Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall, Erqi L. Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica Chiang, Michael Grant, Sarah B. Goldberg, Joshua D. Palmer, Rahul N. Prasad, Tony J.C. Wang, Albert Lee, Catherine A. Shu, Lanyi Nora Chen, Nicholas J.Thomas, Steve E. Braunstein, Brian D.Kavanagh, D. Ross Camidge, and Chad G.Rusthoven.

Additional information
Source: Joshua D. Palmer/X